To kick off the Lift & Co. Cannabis Expo in Toronto, the three-day affair started with a preliminary cannabis business conference, held on Thursday (May 24).
The conference featured a wide array of panels and speakers from different corners of the cannabis industry, from governance and distribution to branding and finance. One panel focused on cannabis development in the retail space touched on how freshly licensed distributors will bring prior “black market” consumers into the legal space.
Panelist Mark Goliger, CEO of National Access Cannabis (TSXV:META), told the Investing News Network (INN) about his company’s plans to integrate products from licensed producers in Canada. Goliger spoke about how many working relationships are currently in progress between both medicinal and recreational cannabis, and said that Tilray is one producer the company has locked down.
The next panel touched on the importance of branding and how some cannabis companies are forced to work their way around restrictive policies when advertising a product through social media.
“We really need to be understanding what the consumer needs are as they evolve,” she said. “Understanding what those consumers need once they’re introduced to the category and what the category involves, more product formats, etc. — I think is going to be critical to how a brand is able to go along with the consumer on that journey.”
One of the afternoon’s final panels honed in on the financial part of the cannabis space and how the investment industry can effectively get in on one of Canada’s hottest up-and-coming commodities.
Martin Landry, GMP Securities’ managing director of equity services, discussed one of the key traits he looks for in a cannabis company when determining its valuation on the market.
“The first thing is the high level of profitability that these companies will achieve,” he said during the panel. “We think that they’re going to be able to generate margins between 25 to 40 percent; these are really high profitability levels. We think they’re going to be able to run at these levels for a couple of years before the division heats up.”
On Friday (May 25), the Lift & Co. Cannabis Expo hit the ground running with an industry day, with panel discussions and vendors as far as the eye could see.
In a conversation revolving around corporate cannabis, and touching on topics such as industry growth and profitability, panelists discussed the importance of maintaining a consistent brand and ideology.
AC Braddock, CEO of Eden Labs and a panelist in the discussion, highlighted the importance of consistency amongst her staff in terms of mentality surrounding both the brand and product.
“This is about a vision-driven industry, it’s about social justice and health and wellbeing. So it isn’t difficult to incorporate all those ideals into your brand, but the most important thing is incorporating those ideals into your team,” she said.
“Your team is the people that are customer facing, so if they don’t believe it, they’re not ingrained in it, it doesn’t [get] from you out to the world,” Braddock added.
One of Friday’s final panels revolved around collaborations, partnerships and M&A activity. Panelist heavyweights included Michael Black, a director at PwC Canada, and Rene Cormier, vice president of corporate finance at KPMG.
Cormier responded to a question about how the market has priced its valuations on certain companies, and what factors into a stock being potentially overvalued or underpriced.
“There’s no silver bullet, there’s no clear-cut answer — you ask different people, you’ll get different answers,” he said. “What I will say is that maybe there’s an important thing [in taking] a step back [to] frame how we think about valuations — so is it fair price or high price or under price? Relative to what?”
Stay tuned as the INN team covers the final two days of the Lift & Co. Cannabis Expo on Saturday (May 26) and Sunday (May 27).
Editor’s Note: This story was updated to correct the name of Martin Landry and his research agency, and to add the ticker symbols of the various public companies mentioned in this article.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Hiku Brands is a client of the Investing News Network. This article is not paid-for content.
Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:
Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.